The pooled breast cancer-specific survival estimates were a 10-year absolute worse difference of 6.8% and a HR of 1.12 (95% CI 0.71–1.53); in contrast, the adjusted HR showed a slightly better breast cancer-specific survival for BRCA1 mutation carriers (0.92, 95% CI 0.58–1.36). The gene discussed is BRCA1; the disease is breast cancer.